You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Antimicrobial stewardship

Antimicrobial prescribing: nebulised liposomal amikacin

  • Evidence summary
  • Reference number: ES36
  • Published:  12 May 2021

This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

Back to top